Velcade

Approved Uses

Velcade is primarily used to treat two specific types of cancer that affect the blood and immune system:

• Multiple Myeloma: This is a cancer of the plasma cells, which are a type of white blood cell in the bone marrow. Velcade is used to treat patients with multiple myeloma, including those who have not been treated before and those whose cancer has returned or progressed after previous treatments.
• Mantle Cell Lymphoma: This is a fast-growing type of non-Hodgkin lymphoma that affects the lymph nodes. Velcade is used for patients with mantle cell lymphoma who have already received at least one other type of treatment.

Velcade is a type of targeted therapy known as a proteasome inhibitor. It may be used as a single agent or in combination with other medications as part of a chemotherapy regimen. It is administered by a healthcare professional as an injection, either into a vein or under the skin.

The Role of Proteasomes

Every cell in the body contains enzymes called proteasomes. These enzymes act like a waste disposal system, breaking down and removing proteins that the cell no longer needs. This process is essential for maintaining the health and normal function of the cell.

How Velcade Affects Cancer Cells

Velcade belongs to a class of medications known as proteasome inhibitors. It works by attaching to these enzymes and preventing them from doing their job. When the proteasomes are blocked, proteins begin to build up inside the cell.

This buildup of excess protein eventually becomes toxic to the cell. Because cancer cells grow and divide more rapidly than healthy cells, they produce more proteins and are more dependent on the proteasome system. As a result, cancer cells are more sensitive to the effects of Velcade than most healthy cells.

Results of Treatment

When the protein levels reach a certain point, the cancer cell receives a signal to stop growing and undergo a process of programmed cell death. This helps to slow the progression of the disease and reduce the number of cancerous cells in the body.

Common Side Effects

Many people receiving Velcade experience side effects during treatment. These often include:

• Digestive problems: Nausea, vomiting, diarrhea, and constipation are very common.
• Fatigue: Feeling unusually tired or weak.
• Nerve issues: Numbness, tingling, or a burning sensation in the hands or feet, known as peripheral neuropathy.
• Blood count changes: A decrease in white blood cells, red blood cells, or platelets, which can increase the risk of infection, anemia, or bruising.
• General symptoms: Fever, headache, loss of appetite, and trouble sleeping.
• Skin reactions: Rash or irritation at the site where the medication was injected.

Serious Side Effects

Some side effects can be severe and may require immediate medical intervention. Contact a healthcare provider if you experience:

• Severe neuropathy: Intense pain or loss of feeling in the limbs that interferes with daily activities.
• Heart and lung issues: Shortness of breath, swelling of the ankles or feet, or a new or worsening cough.
• Liver problems: Yellowing of the skin or eyes (jaundice) and upper stomach pain.
• Low blood pressure: Feeling dizzy, lightheaded, or faint, especially when standing up quickly.
• Tumor Lysis Syndrome: A condition caused by the rapid breakdown of cancer cells, which can lead to kidney failure and heart rhythm problems.
• Brain-related symptoms: Seizures, confusion, or vision loss, which may indicate a rare condition called Posterior Reversible Encephalopathy Syndrome (PRES).
• Severe skin reactions: Widespread rash, skin peeling, or blisters.

Serious Risks and Safety Information

Fatal Administration Warning: Velcade is for subcutaneous or intravenous use only. Administration into the spinal fluid (intrathecal) is fatal.

Nerve and Neurological Issues

• Peripheral Neuropathy: This medication frequently causes nerve damage, resulting in burning, tingling, or numbness in the hands and feet. Dose adjustments or changes in administration may be necessary if symptoms worsen.
• Posterior Reversible Encephalopathy Syndrome (PRES): This rare brain condition can cause seizures, high blood pressure, headaches, and vision loss.

Organ and Systemic Warnings

• Low Blood Pressure: Sudden drops in blood pressure, especially when standing, are common. Caution is advised for patients with a history of fainting or those taking blood pressure medications.
• Heart and Lung Problems: New or worsening heart failure and lung inflammation have been reported.
• Liver Toxicity: Cases of liver failure and hepatitis have occurred during treatment.
• Tumor Lysis Syndrome: The rapid breakdown of cancer cells can cause chemical imbalances that may lead to kidney failure.

Blood and Immune System

Velcade can cause significant decreases in platelets and white blood cells. This increases the risk of bleeding and infections. Blood counts are typically monitored throughout treatment.

Pregnancy and Reproduction

This medication can cause harm to an unborn baby. Effective contraception is recommended during treatment and for a specified period after the final dose. Breastfeeding is not recommended during treatment.

Pregnancy

Velcade can cause harm to a developing fetus. Animal studies have shown that the medication can lead to pregnancy loss or birth defects. Because of these risks, it is important to discuss the benefits and potential dangers with a healthcare provider before starting treatment.

Healthcare providers typically recommend the following precautions:

• Pregnancy testing: Females who are able to become pregnant should have a pregnancy test before starting Velcade.
• Contraception for females: Effective birth control should be used during treatment and for seven months after the final dose.
• Contraception for males: Men with partners who can become pregnant should use effective birth control during treatment and for four months after the last dose.

Breastfeeding

It is currently unknown if Velcade passes into human breast milk. However, because the drug could cause serious side effects in a nursing child, breastfeeding is not recommended during treatment. Most guidelines suggest waiting at least two months after the last dose of Velcade before starting or resuming breastfeeding.

Velcade is available in the following form:

• Lyophilized Powder for Injection: This is a dry, sterile powder supplied in a single-dose vial. It is preservative-free and must be reconstituted (mixed with liquid) by a healthcare provider before use.

Once the powder is mixed into a solution, it can be administered in two different ways:

• Subcutaneous Injection: The medication is injected into the fatty tissue just under the skin, usually in the thigh or abdomen.
• Intravenous Injection: The medication is injected directly into a vein.

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved Velcade in May 2003. Initially, it was approved under an accelerated process for patients with multiple myeloma whose cancer had progressed after receiving other treatments. Since its initial release, the FDA has expanded its approved uses to include both previously untreated and relapsed cases of certain cancers.

Approved Indications

Velcade is currently FDA-approved for the treatment of:

• Multiple myeloma (a type of cancer that forms in a type of white blood cell called a plasma cell).
• Mantle cell lymphoma (a fast-growing type of non-Hodgkin lymphoma).

Important Safety Communications

The FDA has issued critical safety warnings regarding the administration of Velcade. It is approved only for intravenous (into a vein) or subcutaneous (under the skin) injection. The FDA has documented that administration into the spinal fluid (intrathecal administration) is fatal and must be avoided. Healthcare facilities are required to follow specific labeling and preparation procedures to prevent this error.

Regulatory Status

Velcade is a prescription-only chemotherapy agent. It does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program, but it is subject to ongoing post-market safety monitoring. Generic versions of the active ingredient, bortezomib, have also received FDA approval for similar indications.

Factors Affecting Price

The total price of Velcade treatment is influenced by several variables:

• Generic vs. Brand Name: Generic versions of the active ingredient, bortezomib, are available and generally cost less than the brand-name drug.
• Administration Costs: Since Velcade must be administered by a healthcare professional in a medical setting, the total cost usually includes fees for the injection or infusion procedure and the facility.
• Treatment Plan: The dosage and frequency of administration required for your specific condition will affect the total expense over time.

Insurance Coverage

Insurance plans, including Medicare, typically cover Velcade, but the amount you pay out of pocket will depend on your individual plan's deductible and copayment requirements. Patients may also find financial assistance through programs designed to help with the cost of specialty medications.